BRIEF—AbbVie expands collaboration with Calibr

US pharma major AbbVie and Calibr, a non-profit drug discovery division of Scripps Research, have expanded their strategic collaboration to advance several innovative pre-clinical and early-stage clinical assets across AbbVie's core therapeutic growth areas including immunology, oncology, neuroscience and other areas of interest.

This partnership is an expansion of the collaboration AbbVie and Scripps Research formed in 2019 to develop a broad range of potential new and novel therapeutics.

In addition to programs initially named in the collaboration from pre-clinical to investigational new drug (IND) stages of development, Calibr will present to AbbVie a certain number of new discovery targets and preclinical assets of mutual interest for option considerations.

Upon AbbVie's decision to exercise its option to a specific program, Calibr is eligible to receive additional payments from AbbVie, including option exercise fees, success-based development and commercial milestone payments, as well as tiered royalties.